Abstract Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. Case presentation A male patient, who was 70 years of age at the time of diagnosis of multiple myeloma in 2011, relapsed after five lines of therapy, including autologous stem cell transplantation. The patient’s disease, which was considered high risk with a deletion of chromosome 17p, advanced quickly and was triple refractory 2 years after diagnosis leaving few treatment options. He was treated with daratumumab monotherapy in the SIRIUS clinical ...
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1...
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma ...
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (...
Background Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeti...
: Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the ...
Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...
Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number o...
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We ...
BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indi...
Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherap...
Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 i...
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma...
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1...
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma ...
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (...
Background Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeti...
: Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the ...
Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...
Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number o...
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We ...
BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indi...
Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherap...
Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 i...
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma...
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1...
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma ...
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (...